疫苗不止抗体：受疫情研究推动，T 细胞疫苗更趋现实？
Vaccines beyond antibodies: Spurred by pandemic research, are T-cell vaccines moving closer to reality?
机构信息
Freelance journalist, Dublin, Ireland.
出版信息
EMBO Rep. 2021 Nov 4;22(11):e54073. doi: 10.15252/embr.202154073. Epub 2021 Oct 18.
Abstract
Lessons learned from the vaccines against SARS-CoV-2 has encouraged research and vaccine development aimed at mustering strong T cell responses against the pathogen.
摘要
从针对 SARS-CoV-2 的疫苗中吸取的经验教训，鼓励了旨在针对病原体产生强烈 T 细胞反应的研究和疫苗开发。
相似文献
1
Vaccines beyond antibodies: Spurred by pandemic research, are T-cell vaccines moving closer to reality?
EMBO Rep. 2021 Nov 4;22(11):e54073. doi: 10.15252/embr.202154073. Epub 2021 Oct 18.
2
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
Immunity. 2020 Oct 13;53(4):724-732.e7. doi: 10.1016/j.immuni.2020.07.019. Epub 2020 Jul 30.
3
Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
JAMA. 2021 Jun 15;325(23):2370-2380. doi: 10.1001/jama.2021.7563.
4
mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic.
Front Immunol. 2023 Mar 30;14:1155728. doi: 10.3389/fimmu.2023.1155728. eCollection 2023.
5
COVID-19 Vaccine: A comprehensive status report.
Virus Res. 2020 Oct 15;288:198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13.
6
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.
7
Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Front Immunol. 2021 Oct 4;12:726960. doi: 10.3389/fimmu.2021.726960. eCollection 2021.
8
Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
J Virol. 2021 Nov 9;95(23):e0097421. doi: 10.1128/JVI.00974-21. Epub 2021 Sep 15.
9
Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines.
J Infect Dis. 2022 Jan 18;225(2):327-331. doi: 10.1093/infdis/jiab574.
10
The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic.
Front Immunol. 2021 Mar 9;12:637651. doi: 10.3389/fimmu.2021.637651. eCollection 2021.
引用本文的文献
1
Immunizing hearts: exploring the vaccination frontier in heart failure management.
Ann Med Surg (Lond). 2023 Nov 7;86(1):300-307. doi: 10.1097/MS9.0000000000001486. eCollection 2024 Jan.
2
The past, current and future epidemiological dynamic of SARS-CoV-2.
Oxf Open Immunol. 2022 Jun 20;3(1):iqac003. doi: 10.1093/oxfimm/iqac003. eCollection 2022.
3
COVID-19 and tuberculosis: the double whammy of respiratory pathogens.
Eur Respir Rev. 2022 Apr 13;31(164). doi: 10.1183/16000617.0264-2021. Print 2022 Jun 30.
4
Precision Vaccine Development: Cues From Natural Immunity.
Front Immunol. 2022 Feb 10;12:662218. doi: 10.3389/fimmu.2021.662218. eCollection 2021.
本文引用的文献
1
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2.
Nature. 2022 Jan;601(7891):110-117. doi: 10.1038/s41586-021-04186-8. Epub 2021 Nov 10.
2
Cross-reactive CD4 T cells enhance SARS-CoV-2 immune responses upon infection and vaccination.
Science. 2021 Oct 8;374(6564):eabh1823. doi: 10.1126/science.abh1823.
3
Rapid and stable mobilization of CD8 T cells by SARS-CoV-2 mRNA vaccine.
Nature. 2021 Sep;597(7875):268-273. doi: 10.1038/s41586-021-03841-4. Epub 2021 Jul 28.
4
Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2.
NPJ Vaccines. 2021 May 13;6(1):74. doi: 10.1038/s41541-021-00336-1.
5
Correlates of protection against SARS-CoV-2 in rhesus macaques.
Nature. 2021 Feb;590(7847):630-634. doi: 10.1038/s41586-020-03041-6. Epub 2020 Dec 4.
6
Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract.
Vaccines (Basel). 2020 Oct 21;8(4):621. doi: 10.3390/vaccines8040621.
7
Recent endemic coronavirus infection is associated with less-severe COVID-19.
J Clin Invest. 2021 Jan 4;131(1). doi: 10.1172/JCI143380.
8
Cutting Edge: The Use of Topical Aminoglycosides as an Effective Pull in "Prime and Pull" Vaccine Strategy.
J Immunol. 2020 Apr 1;204(7):1703-1707. doi: 10.4049/jimmunol.1900462. Epub 2020 Mar 2.
9
Prevention of tuberculosis in macaques after intravenous BCG immunization.
Nature. 2020 Jan;577(7788):95-102. doi: 10.1038/s41586-019-1817-8. Epub 2020 Jan 1.
10
A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge.
Sci Transl Med. 2019 Jul 17;11(501). doi: 10.1126/scitranslmed.aaw2607.
Zotero 插件